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propertiesAbstract The a-hydroxyphosphonate generated from dialkyl phosphites and 1-phenyl-1H-
pyrazole-4-carbaldehyde derivative was, in situ, trapped by isothiocyanates, isocyanates or acetic
anhydride to produce dialkyl phosphorylmethyl-carbamothioates, -carbamates and/or -methyl
acetates in good yields. The reactions were carried out in tetrahydrofuran (THF) in one step at
room temperature, using K2CO3 catalyst. Antimicrobial and antineoplastic activities of the synthe-
sized compounds were estimated. The results showed that all new compounds cause moderate to
good antibiotic activities. However, phosphorylmethylcarbamothioates exhibited the highest
growth inhibition. Furthermore, selected nine new synthesized compounds were evaluated for anti-
cancer activity against eight human tumor cell lines (MCF7,MDA-MB-435, BT-549, IGROVI, SK-
OV-3, PX-3, PU-145, and HEPG2). The majority of these compounds revealed moderate to potent
activity against MCF7, PU-145, and HEPG2. Among them, two of the phosphorylmethylcarbamo
thioates showed excellent broad spectrum of anticancer activity with IC50 values ranging from 16.6
to 26.9 and 17.2 to 36.9 lmol L1, respectively (for 5-ﬂuorouracil IC50: 17.7 to 38.8 lmol L
1).
Phosphorylmethyl methylcarbamothioate, in particular was more potent than 5-ﬂuorouracil against
all tested human carcinoma cell lines.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Currently, cancer is among the most critical health issues
and considered to be the second leading cause of death
worldwide, just behind cardiovascular diseases (Varmus,
2006). Tremendous progress has been made in the war against
cancer diseases with the development of many new chemother-
apy agents (Harrison et al., 2009), such as paclitaxel, docetaxel
(Kingston and Newman, 2007) and ixabepilone (Hunt, 2009),
as well as small molecule targeted therapies (Baselga, 2006)antineo-
2 W.M. Abdou, M.S. Bekheitsuch as imatinib (Cross and Lyseng-Williamson, 2007) and
sorafenib (Wood and Manchen, 2007). Nevertheless, due to
the toxicity, problems of mutagenicity, and drug resistance
of many currently available treatments, it remains a great chal-
lenge to discover and develop more effective drugs to conquer
cancer diseases (Varmus, 2006).
In parallel, because of the widespread resistance to antimi-
crobial drugs, there is an increasing need for developing lead-
structures that may be of use in designing new potent and less
toxic antimicrobial agents. Furthermore, as it is stated that the
antitumor efﬁcacy of many chemotherapeutic agents in many
occasions is correlated with antibiotic properties (Sievert
et al., 2002; Bremner et al., 2007), new approaches to promote
anti-proliferation and apoptosis in cancer cells along with
enhancing the antibiotic activity could lead to the development
of dual/multiple targets (Hubschwerlen et al., 2003). In addi-
tion, these new agents may overcome tumor resistance. In
sequel, and in continuation of our cancer-treatment (Abdou
et al., 2012a,b,c,d, 2013a,b; Kamel et al., 2012) and antibiotic
research programs (Abdou et al., 2009a,b, 2014b,c; Abdou and
Khidre, 2010), we have recently considered the anticancer–an-
tibiotic relationship studies (Abdou et al., 2014a).
Over the last three decades, organophosphorus compounds
have been notably recognized for their pharmacological anti-
cancer (Pratt, 1989; Wardle et al., 2005) and antibiotic activity
(Duncanson et al., 2012), especially when they are associated
with various heterocycles (Franco et al., 1995). One of the
most important of these bioactive heterocycles is the pyrazole
nucleus (Lee et al., 2003; Elguero, 1996).
We have focused, in this work on the synthesis of
dialkoxyphosphoryl peptides. The demand for modiﬁed pep-
tides with improved stability proﬁles and pharmacokinetic
properties is driving extensive research efforts in this ﬁeld.
Many structural modiﬁcations of peptides guided by rational
design and molecular modeling have been established to
develop novel synthetic approaches (Goodman, 2003).2. Material and methods
2.1. General data
Melting points were determined with an open capillary tube on
an Electrothermal (variable heater, Stuart, UK) melting point
apparatus and were corrected. IR spectra were recorded on a
JASCO FT-IR 6100 using KBr disk (JASCO, Japan). NMR
spectra were measured with a JEOL E.C.A-500 MHz (13C:
125.4 MHz, 1H: 500.7 MHz, 31P: 200.7 MHz) spectrometer
(JEOL, Japan). 31P NMR spectra were recorded with H3PO4
(85%) as external reference; 1H and 13C NMR spectra were
recorded with trimethylsilane as internal standard in CDCl3
or DMSO-d6. Chemical shifts (d) are given in ppm. The mass
spectra were recorded at 70 eV on an MS-50 Kratos (A.E.I.)
spectrometer (Kratos, UK) provided with a data system.
Elemental analyses were carried out at the Microanalysis
Laboratory, Cairo University, Cairo, Egypt, using elementary
Analysensysteme GmbH-vario EL III Element Analyzer,
Germany. Staring aldehyde, 3-(benzofuran-2-yl)-1-phenyl-
1H-pyrazole-4-carbaldehyde (1) was obtained using the proce-
dure reported elsewhere (Goudarshivannanavar et al., 2009).
Solvents were dried by standard techniques: TLC, Merck
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phosphorylmethyl-carbamothioates 5a–5j, -carbamates 6a, 6b
and -methylacetate 7a, 7b
A mixture of dimethyl (2a) or diethyl phosphite (2b, 3.4 mmol),
3-(benzofuran-2-yl)-1-methyl-1H-pyrazole-4-carbaldehyde (1,
3.4 mmol) inTHF(10 mL), andpotassiumcarbonate (5.1 mmol)
was stirred for 10 min at room temperature. A solution of isoth-
iocyanates: methyl-, ethyl-, cyclohexane-, phenyl- (3d), or allyl-
isothiocyanate (3a–d, f), as well as phenylisocyanate (3e), or
acetic anhydride (3.4 mmol) in 5 mL THF was then added in
one portion; and the reaction mixture was stirred at room tem-
perature for the appropriate time (4–6 h). After completion of
the reaction (TLC), the mixture was ﬁltered off and the solid
K2CO3 washed several times with AcOEt. After removal of the
evaporated materials under vacuum, the resulting residue was
crystallized from the proper solvent to give the corresponding
phosphonate 5a–j, 6a, 6b, 7a, or 7b, respectively.
2.2.1. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-
yl)(dimethoxyphosphoryl)methyl-methylcarbamothioate (5a)
Colorless crystals from ethanol, mp 183 C, yield: 78%. IR
(cm1, KBr): mmax 3364 (NH), 1256 (P‚O), 1130 (C‚S),
1077 (PAOAC). 1H NMR (DMSO-d6) ppm: d 3.33 (s, 3H,
MeN), 3.59, 3.67 (2d, 3JPAH = 10.5 Hz, 2 · 3H, (MeCO)2P),
5.42 (d, 2JPAH = 15.5 Hz, 1H, HC-P), 6.42 (br, 1H, HN),
7.33–7.92 (m, 10H, HAAr & hetero), 8.62 (s, 1H,
H-pyrazole).13C NMR (DMSO-d6) ppm: d 180.2 (d,
3JPAC = 8.1 Hz, C‚S), 152.8, 141.7, 141.1, 128.9, 128.4,
126.2, 125.1, 124.4, 122.0, 119.6, 111.4, 109.2 (CAAr & hetero),
136.1 (3JPAC = 8.6 Hz, C(3)-pyrazole), 130.2 (d,
2JPAC =
14.2 Hz, C(4)-pyrazole), 126.2 (3JPAC = 10.2 Hz, C(5)-
pyrazole), 68.9 (d, 1JPAC = 121.5 Hz, HCP), 53.5 (d,
2JPAC = 8.8 Hz, MeOP), 31.2 (N-Me).
31P NMR (DMSO-d6)
ppm: d 22.6. EI-MS: in m/z (%): 471 (18) [M+], 470 (37)
[M+  1], 288 (100) [M+  (C(S)NHMe + P(O)(OMe)2)].
Anal. Calcd for C22H22N3O5PS (471.1): C, 56.05; H, 4.70;
N, 8.91; P, 6.57; S, 6.80. Found: C, 56.11; H, 4.62; N, 8.78; P,
6.66; S, 6.93.
2.2.2. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)
(diethoxyphosphoryl)methyl methylcarbamothioate (5b)
Colorless crystals from ethanol, mp 161.5 C, yield: 70%. IR
(cm1, KBr): mmax 3419 (NH), 1249 (P‚O), 1132 (C‚S),
1063 (PAOAC). 1H NMR (DMSO-d6) ppm: d 1.24, 1.26 (2dt,
3JHAH = 6.7,
4JPAH = 4.4 Hz, 2 · 3H, (Me.CO)2P), 3.36 (s,
3H, MeN), 4.15, 4.30 (2dq, 3JHAH = 6.7,
3JPAH = 6.2 Hz,
2 · 2H, (CH2O)2P), 5.63 (d, 2JPAH = 17.8 Hz, 1H, HCAP),
7.31–7.92 (m, 10H, HAAr & hetero), 8.57 (s, 1H, H-
pyrazole), 9.52 (br, 1H, HN). 13C NMR (DMSO-d6) ppm: d
180.4 (d, 3JPAC = 8.4 Hz, C‚S), 152.7, 141.6, 141.1, 128.8,
128.3, 126.1, 125.1, 124.6, 122.6, 119.3, 111.1, 109.2 (CAAr &
hetero), 136.1 (3JPAC = 8.8 Hz, C(3)-pyrazole), 130.2 (d,
2JPAC = 14.7 Hz, C(4)-pyrazole), 126.2 (
3JPAC = 10.2 Hz,
C(5)-pyrazole), 70.1 (d, 1JPAC = 120.6 Hz, HCP), 64.7 (d,
2JPAC = 7.8 Hz, H2COP), 31.6 (N-Me), 16.5 (d,
3JPAC = 6.8 Hz, Me.COP).
31P NMR (DMSO-d6) ppm: d
23.9. EI-MS: in m/z (%): 499 (23) [M+], 498 (35) [M+  1],
288 (100) [M+  (C(S)NHMe + P(O)(OEt)2)]. Anal. Calcd
for C24H26N3O5PS (499.1): C, 57.71; H, 5.25; N, 8.41; P, 6.20;
S, 6.42. Found: C, 57.80; H, 5.12; N, 8.27; P, 6.23; S, 6.55.onent synthesis of peptidomimics for investigation of antibacterial and antineo-
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Peptidomimics vs microbial and cancer diseases 32.2.3. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)
(dimethoxyphosphoryl)methyl-ethylcarbamothioate (5c)
Colorless crystals from ethanol, mp 176 C, yield: 75%. IR
(cm1, KBr): mmax 3332 (NH), 1256 (P‚O), 1138 (C‚S), 1075
(PAOAC). 1H NMR (CDCl3) ppm: d 1.20 (t,
3JHAH = 6.4,
3H, MeCAN), 3.60 (q, 3JHAH = 6.4 Hz, 2H, CH2N), 3.68,
3.82 (2d, 3JPAH = 11.4 Hz, 2 · 3H, (MeO)2P), 5.60
(d, 2JPAH = 16.2 Hz, 1H, HCAP), 6.41 (br, 1H, HN),
7.25–7.78 (m, 10H, HAAr & hetero), 8.41 (s, 1H, H-pyrazole).
13C NMR (CDCl3) ppm: d 180.9 (d,
3JPAC = 8.2 Hz, C‚S),
152.8, 141.5, 140.8, 128.8, 128.1, 126.1, 125.1, 124.6, 122.0,
119.6, 111.8, 108.8 (CAAr & hetero), 136.2 (3JPAC = 9.6 Hz,
C(3)-pyrazole), 130.1 (d, 2JPAC = 14.7 Hz, C(4)-pyrazole),
126.2 (3JPAC = 9.8 Hz, C(5)-pyrazole), 69.7 (d,
1JPAC = 124.2 Hz, HCP), 53.5 (d,
2JPAC = 7.2 Hz, MeOP),
43.1 (NACH2), 41.2 (NACMe).
31P NMR (CDCl3) ppm:
d 20.5. EI-MS: in m/z (%): 485 (38) [M+], 484 (56) [M+  1],
288 (100) [M+  (C(S)NHEt + P(O)(OMe)2)]. Anal. Calcd
for C23H24N3O5PS (485.1): C, 56.90; H, 4.98; N, 8.66; P, 6.38;
S, 6.60. Found: C, 56.82; H, 4.92; N, 8.55; P, 6.29; S, 6.72.
2.2.4. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)
(diethoxyphosphoryl)methyl ethylcarbamothioate (5d)
Colorless crystals from ethanol, mp 143 C, yield: 70%. IR
(cm1, KBr): mmax 3421 (NH), 1255 (P‚O), 1134 (C‚S), 1035
(PAOAC). 1H NMR (CDCl3) ppm: d 1.18 (t,
3JHAH = 7.6,
3H, MeCAN), 1.28, 1.32 (2dt, 3JHAH = 7.8,
4JPAH = 5.4 Hz,
2 · 3H, (Me.CO)2P), 3.48 (q, 3JHAH = 7.6 Hz, 2H, CH2N),
4.17, 4.20 (2dq, 3JHAH = 7.8,
3JPAH = 10.8 Hz, 2 · 2H,
(CH2O)2P), 5.58 (d,
2JPAH = 16.6 Hz, 1H, HCAP), 7.25–7.78
(m, 10H, HAAr & hetero), 8.38 (s, 1H, H-pyrazole), 8.58 (br,
1H, HN). 13C NMR (CDCl3) ppm: d 180.7 (d,
3JPAC = 8.2 Hz, C‚S), 152.2, 141.6, 141.1, 128.3, 127.7,
126.1, 125.6, 124.2, 122.1, 119.0, 111.2, 108.9 (CAAr & hetero),
136.5 (3JPAC = 9.2 Hz, C(3)-pyrazole), 130.1 (d,
2JPAC = 13.8 Hz, C(4)-pyrazole), 126.0 (
3JPAC = 10.4 Hz,
C(5)-pyrazole), 71.1 (d, 1JPAC = 121.3 Hz, HCP), 64.5
(d, 2JPAC = 8.6 Hz, H2COP), 43.2 (NACH2), 41.5 (NACMe),
16.4 (d, 3JPAC = 7.5 Hz, Me.COP).
31P NMR (CDCl3) ppm:
d 19.7. EI-MS: in m/z (%): 513 (28) [M+], 512 (49) [M+  1],
288 (100) [M+  (C(S)NHEt + P(O)(OEt)2)]. Anal.
Calcd for C25H28N3O5PS (513.1): C, 58.47; H, 5.50;
N, 8.18; P, 6.03; S, 6.24. Found: 58.37; H, 5.56; N, 8.25; P,
5.59; S, 6.35.
2.2.5. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)
(dimethoxyphosphoryl)methyl cyclohexylcarbamo-thioate (5e)
Colorless crystals from ethanol, mp 176 C, yield: 62%. IR
(cm1, KBr): mmax 3372 (NH), 1256 (P‚O), 1136 (C‚S),
1076 (PAOAC). 1H NMR (DMSO-d6) ppm: d 1.32–2.02
(m, 10H, CH2
chex), 3.32 (m, 1H, H-chex), 3.64, 3.72
(2d, 3JPAH = 10.8 Hz, 2 · 3H, (MeO)2P), 5.41 (d, 2JPAH =
20.2 Hz, 1H, HCAP), 6.39 (br, 1H, HN), 7.28–7.92 (m, 10H,
HAAr & hetero), 8.39 (s, 1H, H-pyrazole). 13C NMR
(DMSO-d6) ppm: d 183.9 (d, 3JPAC = 8.3 Hz, C‚S), 152.6,
141.6, 141.0, 128. 5, 128.1, 126.1, 125.3, 124.9, 121.8, 119.6,
112.0, 109.0 (CAAr & hetero), 136.0 (3JPAC = 10.2 Hz, C(3)-
pyrazole), 130.3 (d, 2JPAC = 14.2 Hz, C(4)-pyrazole), 126.2
(3JPAC = 10.2 Hz, C(5)-pyrazole), 69.7 (d,
1JPAC = 122.1 Hz,
HCP), 54.2 (CH-chex), 53.6 (d, 2JPAC = 7.4 Hz, MeOP),
39.7, 25.4, 24.2 (C-chex). 31P NMR (DMSO-d6) ppm: d 23.1.Please cite this article in press as: Abdou, W.M., Bekheit, M.S. One-pot three-comp
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(100) [M+  (C(S)NH-chex + P(O)(OMe)2)]. Anal. Calcd for
C27H30N3O5PS (539.1): C, 60.10; H, 5.60; N, 7.79; P, 5.74; S,
5.94. Found: 60.21; H, 5.55; N, 7.68; P, 5.79; S, 6.88.
2.2.6. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)
(diethoxyphosphoryl)methyl cyclohexylcarbamo-thioate (5f)
Colorless crystals from ethanol, mp 149 C, yield: 64%. IR
(cm1, KBr): mmax 3415 (NH), 1254 (P‚O, free), 1130
(C‚S), 1060 (PAOAC). 1H NMR (CDCl3) ppm: d 1.24,
1.28 (2dt, 3JHAH = 7.4,
4JPAH = 5.6 Hz, 2 · 3H,
(Me.CO)2P), 1.30–2.04 (m, 10H, CH2
chex), 3.43 (m, 1H,
H-chex), 4.18, 4.24 (2dq, 3JHAH = 7.4,
3JPAH = 10.4 Hz,
2 · 2H, (CH2O)2P), 5.71 (d, 2JPAH = 14.7 Hz, 1H, HCAP),
6.86 (br, 1H, HN), 7.25–7.72 (m, 10H, HAAr & hetero),
8.36 (s, 1H, H-pyrazole). 13C NMR (CDCl3) ppm: d 183.7
(d, 3JPAC = 8.6 Hz, C‚S), 152.5, 141.3, 139.8, 128.4, 128.0,
126.1, 125.2, 124.8, 121.8, 119.5, 112.1, 108.7 (CAAr & het-
ero), 136.2 (3JPAC = 8.9 Hz, C(3)-pyrazole), 130.2 (d,
2JPAC = 14.5 Hz, C(4)-pyrazole), 126.2 (
3JPAC = 9.8 Hz,
C(5)-pyrazole), 69.5 (d, 1JPAC = 125.4 Hz, HCP), 64.3 (d,
2JPAC = 7.6 Hz, H2COP), 53.8 (CH-
chex), 31.3, 25.6, 24.6
(C-chex), 16.4 (d, 3JPAC = 7.3 Hz, Me.COP).
31P NMR
(CDCl3) ppm: d 20.8. EI-MS: in m/z (%): 567 (45) [M
+],
566 (65) [M+  1], 288 (100) [M+  (C(S)NH-chex +
P(O)(OEt)2)]. Anal. Calcd for C29H34N3O5PS (567.2): C,
61.36; H, 6.04; N, 7.40; P, 5.46; S, 5.65. Found: C, 61.45; H,
5.95; N, 7.33; P, 5.38; S, 5.76.
2.2.7. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-
yl)(dimethoxyphosphoryl)methyl phenylcarbamothioate (5g)
Colorless crystals from ethanol, mp 146 C, yield: 66%. IR
(cm1, KBr): mmax 3417 (NH), 1262 (P‚O), 1124 (C‚S),
1035 (PAOAC). 1H NMR (DMSO-d6) ppm: d 3.62, 3.72 (2d,
3JPAH = 10.5 Hz, 2 · 3H, (MeO)2P), 5.42 (d,
2JPAH = 17.6 Hz, 1H, HCAP), 6.12 (br, 1H, HN), 7.22–7.73
(m, 15H, HAAr & hetero), 8.32 (s, 1H, H-pyrazole). 13C
NMR (DMSO-d6) ppm: d 180.1 (d, 3JPAC = 8.4 Hz, C‚S),
152.5, 141.7, 141.2, 138.3, 129.0, 128.8, 128.3, 126.1, 125.5,
125.0, 124.4, 121.3, 120.4, 119.4, 111.7, 109.2 (CAAr & het-
ero), 135.9 (3JPAC = 8.8 Hz, C(3)-pyrazole), 130.4 (d,
2JPAC = 14.7 Hz, C(4)-pyrazole), 126.3 (
3JPAC = 10.2 Hz,
C(5)-pyrazole), 66.1 (d, 1JPAC = 124.8 Hz, HCP), 53.6 (d,
2JPAC = 7.4 Hz, MeOP).
31P NMR (DMSO-d6) ppm: d 21.8.
EI-MS: in m/z (%): 533 (24) [M+], 532 (57) [M+  1], 288
(100) [M+  (C(S)NHPh + P(O)(OMe2)]. Anal. Calcd for
C27H24N3O5PS (533.1): C, 60.78; H, 4.53; N, 7.88; P, 5.81; S,
6.01. Found: C, 60.88; H, 4.47; N 7.79; P, 5.82; S, 6.14.
2.2.8. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-
yl)(diethoxyphosphoryl)methyl phenylcarbamothioate (5h)
Colorless crystals from ethanol, mp 140 C, yield: 78%. IR
(cm1, KBr): mmax 3399 (NH), 1257 (P‚O), 1137 (C‚S),
1033 (PAOAC). 1H NMR (DMSO-d6) ppm: d 1.04, 1.11
(2dt, 3JHAH = 8.6,
4JPAH = 4.5 Hz, 2 · 3H, (Me.CO)2P),
4.03, 4.12 (2dq, 3JHAH = 8.6,
3JPAH = 10.2 Hz, 2 · 2H,
(CH2O)2P), 5.37 (d,
2JPAH = 16.8 Hz, 1H, HCAP), 6.37 (br,
1H, HN), 7.26–7.92 (m, 15H, HAAr & hetero), 8.58 (s, 1H,
H-pyrazole). 13C NMR (DMSO-d6) ppm: d 180.7 (d,
3JPAC = 7.9 Hz, C‚S), 152.5, 141.6, 140.8, 138.3, 129.2,
128.5, 128.0, 126.1, 125.8, 124.8, 124.0, 121.3, 120.4, 118.9,onent synthesis of peptidomimics for investigation of antibacterial and antineo-
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pyrazole), 133.2 (d, 2JPAC = 14.5 Hz, C(4)-pyrazole), 126.5
(3JPAC = 11.2 Hz, C(5)-pyrazole), 66.3 (d,
1JPAC = 127.3 Hz,
HCP), 64.4 (d, 2JPAC = 7.8 Hz, H2COP), 15.9 (d,
3JPAC = 7.9 Hz, Me.COP).
31P NMR (DMSO-d6) ppm: d
20.4. EI-MS: in m/z (%): 561 (31) [M+], 560 (53) [M+  1],
288 (100) [M+  (C(S)NHPh + P(O)(OEt)2)]. Anal. Calcd
for C29H28N3O5PS (561.1): C, 62.02; H, 5.03; N, 7.48; P,
5.52; S, 5.71. Found: C, 62.20; H, 4.95; N, 7.42; P, 5.63; S, 5.81.
2.2.9. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-
yl)(dimethoxyphosphoryl)methyl phenylcarbamate (5i)
Colorless crystals from ethanol, mp 174 C, yield: 82%. IR
(cm1, KBr): mmax 3341 (NH), 1703 (C‚O), 1256 (P‚O),
1075 (PAOAC). 1H NMR (CDCl3) ppm: d 3.06 (br, 1H,
HN), 3.69, 3.82 (2d, 3JPAH = 12.3 Hz, 2 · 3H, (MeO)2P),
5.62 (d, 2JPAH = 14.6 Hz, 1H, HCAP), 7.25–7.77 (m, 15H,
HAAr & hetero), 8.41 (s, 1H, H-pyrazole). 13C NMR
(CDCl3) ppm: d 154.2 (d,
3JPAC = 6.5 Hz, C‚O), 150.9,
140.7, 139.8, 138.1, 128.9, 128.5, 127.3, 126.0, 125.5, 124.8,
123.7, 120.9, 120.3, 119.1, 111.7, 109.4 (CAAr & hetero),
135.8 (3JPAC = 8.6 Hz, C(3)-pyrazole), 130.1 (d,
2JPAC = 14.3 Hz, C(4)-pyrazole), 126.4 (
3JPAC = 10.8 Hz,
C(5)-pyrazole), 68.1 (d, 1JPAC = 125.6 Hz, HCP), 53.1 (d,
2JPAC = 7.2 Hz, MeOP).
31P NMR (CDCl3) ppm: d 23.9.
EI-MS: in m/z (%): 517 (28) [M+], 516 (42) [M+  1], 288
(100) [M+  (C(O)NHPh + P(O)(OMe)2)]. Anal. Calcd for
C27H24N3O6P (517.1): C, 62.67; H, 4.67; N, 8.12; P, 5.99.
Found: C, 62.54; H, 4.59; N, 8.03; P, 6.22.
2.2.10. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-
yl)(diethoxyphosphoryl)methyl phenylcarbamate (5j)
Colorless crystals from ethanol, mp 148.5 C, yield:
80%. IR (cm1, KBr): mmax 3365 (NH), 1742 (C‚O), 1258
(P‚O), 1062 (PAOAC). 1H NMR (DMSO-d6) ppm: d 1.04,
1.19 (2dt, 3JHAH = 6.7,
4JPAH = 4.4 Hz, 2 · 3H,
(Me.CO)2P), 4.03, 4.16 (2dq,
3JHAH = 6.7,
3JPAH = 11.2 Hz,
2 · 2H, (CH2O)2P), 5.37 (d, 2JPAH = 21.4 Hz, 1H, HCAP),
6.40 (br, 1H, HN), 7.26–7.91 (m, 15H, HAAr & hetero),
8.58 (s, 1H, H-pyrazole). 13C NMR (DMSO-d6) ppm: d
153.8 (d, 3JPAC = 6.4 Hz, C‚O), 151.2, 141.0, 138.6, 137.6,
128.7, 128.1, 127.2, 126.3, 125.2, 124.8, 124.3, 120.8, 120.2,
119.4, 111.8, 109.1 (CAAr & hetero), 135.1 (3JPAC = 8.6 Hz,
C(3)-pyrazole), 130.4 (d, 2JPAC = 14.4 Hz, C(4)-pyrazole),
125.9 (3JPAC = 10.2 Hz, C(5)-pyrazole), 68.7 (d,
1JPAC = 124.6 Hz, HCP), 64.3 (d,
2JPAC = 7.9 Hz,
H2COP),16.0 (d,
3JPAC = 7.5 Hz, Me.COP).
31P NMR
(DMSO-d6) ppm: d 22.4. EI-MS: in m/z (%): 545 (27) [M+],
544 (30) [M+  1], 288 (100) [M+  (C(O)NHPh +
P(O)(OEt)2)]. Anal. Calcd for C29H28N3O6P (545.1): C,
63.85; H, 5.17; N, 7.70; P, 5.68. Found: C, 63.91; H, 5.28; N,
7.56; P, 5.62.
2.2.11. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-
yl)(dimethoxyphosphoryl)methyl propylidenecarbamo-thioate
(6a)
Colorless crystals from ethanol, mp 179 C, yield: 70%. IR
(cm1, KBr): mmax 1610 (N‚C, exocycl), 1134 (C‚S), 1251
(P‚O), 1068 (PAOAC). 1H NMR (DMSO-d6) ppm: d 2.33
(t, JHAH = 6.7, 3H, MeCH2), 3.44 (m, 2H, H2C-Me), 3.66,
3.68 (2d, 3JPAH = 11.8 Hz, 2 · 3H, (MeCO)2P), 5.42 (d,Please cite this article in press as: Abdou, W.M., Bekheit, M.S. One-pot three-comp
plastic properties. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.2JPAH = 17.4 Hz, 1H, HCAP), 6.46 (t, JHAH = 6.6 Hz, 1H,
N‚CH-exocycl), 7.35–7.92 (m, 10H, HAAr & hetero), 8.60
(s, 1H, H-pyrazole). 13C NMR (DMSO-d6) ppm: d 185.2 (d,
3JPAC = 7.5 Hz, C‚S), 164.8 (N‚CH-exocycl), 152.6,
141.8, 141.1, 128.9, 128.1, 126.2, 125.4, 124.3, 122.4, 119.2,
111.3, 109.4 (CAAr & hetero), 135.2 (3JPAC = 8.8 Hz, C(3)-
pyrazole), 130.5 (d, 2JPAC = 14.7 Hz, C(4)-pyrazole), 126.2
(3JPAC = 10.2 Hz, C(5)-pyrazole), 71.9 (d,
1JPAC = 123.4 Hz,
HCP), 53.0 (d, 2JPAC = 7.8 Hz, MeOP), 18.7 (N‚CCH2),
11.1 (CACH3).
31P NMR (DMSO-d6) ppm: d 24.1. EI-MS:
in m/z (%): 497 (29) [M+], 496 (53) [M+  1], 288 (100)
[M+  (C(S)C3H6 + P(O)(OMe)2)]. Anal. Calcd for
C24H24N3O5P S (497.1): C, 57.94; H, 4.86; N, 8.45; P, 6.23;
S, 6.45. Found: C, 58.07; H, 4.80; N, 8.37; P, 6.33; S, 6.51.2.2.12. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-
yl)(diethoxyphosphoryl)methyl propylidenecarbamo-thioate
(6b)
Colorless crystals from ethanol, mp 158 C, yield: 74%. IR
(cm1, KBr): mmax 1605 (N‚C, exocycl), 1136 (C‚S), 1258
(P‚O), 1064 (PAOAC). 1H NMR (DMSO-d6) ppm: d 1.12,
1.24 (2dt, 3JHAH = 7.6,
4JPAH = 4.4 Hz, 2 · 3H,
(Me.CO)2P), 2.24 (t, JHAH = 6.4, 3H, CH2Me), 3.52 (m, 2H,
H2CMe), 4.08, 4.12 (2dq,
3JHAH = 7.6,
3JPAH = 6.2 Hz,
2 · 2H, (CH2O)2P), 5.36 (d, 2JPAH = 18.6 Hz, 1H, HCAP),
6.35 (t, JHAH = 6.5 Hz, 1H, N‚CH-exocycl), 7.26–7.92 (m,
10H, HAAr & hetero), 8.58 (s, 1H, H-pyrazole). 13C NMR
(DMSO-d6) ppm: d 184.8 (d, 3JPAC = 7.2 Hz, C‚S),164.6
(N‚CH-exocycl), 152.2, 141.5, 141.0, 128.8, 128.1, 126.1,
125.2, 124.0, 122.4, 119.1, 112.1, 108.9 (CAAr & hetero),
135.4 (3JPAC = 8.6 Hz, C(3)-pyrazole), 130.3
(d, 2JPAC = 14.7 Hz, C(4)-pyrazole), 126.1 (
3JPAC = 9.6 Hz,
C(5)-pyrazole), 72.4 (d, 1JPAC = 124.5 Hz, HCP), 63.9
(d, 2JPAC = 7.6 Hz, H2COP), 15.8 (d,
3JPAC = 7.7 Hz,
Me.COP), 18.2 (N‚CCH2), 11.4 (CACH3).
31P NMR
(DMSO-d6) ppm: d 23.7. EI-MS: in m/z (%): 525 (33) [M+],
288 (100) [M+  (C(S)NHC3H6 + P(O)(OEt)2)]. Anal. Calcd
for C26H28N3O5PS (525.1): C, 59.42; H, 5.37; N, 8.00;
P, 5.89; S, 6.10. Found: C, 59.31; H, 5.8; N, 7.84; P,
5.94 S, 6.23.2.2.13. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-
yl)(dimethoxyphosphoryl)methyl acetate (7a)
Colorless crystals from ethanol, mp 149 C, yield: 82%. IR
(cm1, KBr): mmax 1754 (C‚O), 1253 (P‚O), 1050
(PAOAC). 1H NMR (DMSO-d6) ppm: d 2.12 (s, H,
C(O)Me), 3.73, 3.78 (2d, 3JPAH = 11.0 Hz, 2 · 3H,
(MeCO)2P), 6.64 (d,
2JPAH = 14.6 Hz, 1H, HCAP), 7.33–
7.95 (m, 10H, HAAr & hetero), 8.73 (s, 1H, H-pyrazole).
13C NMR (DMSO-d6) ppm: d 166.9 (d, 3JPAC = 8.4 Hz,
C‚O), 152.7, 141.7, 141.3, 128.5, 128.1, 126.2, 124.9, 124.2,
122.3, 119.2, 111.3, 109.5 (CAAr & hetero), 136.1
(3JPAC = 8.8 Hz, C(3)-pyrazole), 129.8 (d,
2JPAC = 14.2 Hz,
C(4)-pyrazole), 126.6 (3JPAC = 9.8 Hz, C(5)-pyrazole), 65.7
(d, 1JPAC = 126.2 Hz, HCP), 53.1 (d,
2JPAC = 7.4 Hz,
MeOP), 20.6 (C(O)Me). 31P NMR (DMSO-d6) ppm: d 26.7.
EI-MS: in m/z (%): 440(45) [M+], 331 (7) [M+  109
(P(OMe)2], 288 (100) [M
+  (C(O)Me + P(O)(OMe)2)].
Anal. Calcd for C22H21N2O6P (440.1): C, 60.00; H, 4.81; N,
6.36; P, 7.03. Found: Found: C, 60.21 H, 4.72; N, 6.45; P, 7.17.onent synthesis of peptidomimics for investigation of antibacterial and antineo-
arabjc.2015.04.014
Peptidomimics vs microbial and cancer diseases 52.2.14. (3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)
(diethoxyphosphoryl)methyl acetate (7b)
Colorless crystals from ethanol, mp 129 C, yield: 86%. IR
(cm1, KBr): mmax 1750 (C‚O), 1260 (P‚O), 1058
(PAOAC). 1H NMR (DMSO-d6) ppm: d 2.19 (s, H,
C(O)Me), 1.06, 1.13 (2dt, 3JHAH = 6.5,
4JPAH = 6.8 Hz,
2 · 3H, (Me.CO)2P), 4.07, 4.22 (2dq, 3JPAH = 11.0 Hz,
2 · 2H, (CH2O)2P), 5.59 (d, 2JPAH = 12.4 Hz, 1H, HCAP),
7.28–7.94 (m, 10H, HAAr & hetero), 8.70 (s, 1H, H-
pyrazole). 13C NMR (DMSO-d6) ppm: d 167.1 (d,
3JPAC = 8.2 Hz, C‚O), 152.2, 141.7, 141.0, 128.9, 128.3,
126.3, 125.4, 124.2, 121.8, 119.1, 111.2, 108.9 (CAAr &
hetero), 136.2 (3JPAC = 8.6 Hz, C(3)-pyrazole), 130.0 (d,
2JPAC = 14.7 Hz, C(4)-pyrazole), 125.9 (
3JPAC = 10.6 Hz,
C(5)-pyrazole), 66.7 (d, 1JPAC = 127.3 Hz, HCP), 64.2
(d, 2JPAC = 7.8 Hz, H2COP), 20.9 (C(O)CH3), 16.1
(d, 3JPAC = 7.5 Hz, Me.COP).
31P NMR (DMSO-d6) ppm: d
26.2. EI-MS: in m/z (%): 468 (43) [M+], 331 (12) [M+  109
(P(OEt)2], 288 (100) [M
+  (C(O)Me + P(O)(OEt)2)]. Anal.
Calcd for C24H25N2O6P (468.1): C, 61.54; H, 5.38; N, 5.98;
P, 6.61. Found: C, 61.60; H, 5.21; N, 5.88; P, 6.75.
2.3. Pharmacological evaluation
2.3.1. Antimicrobial activity
The antimicrobial activity of the synthesized phosphonates 5a–
5j, 6a, 6b, 7a and 7b was individually tested against a panel of
Gram negative: Klebsiella pneumoniae 2011E, Pseudomonas
aeruginosa 6065 Y; Escherichia coli BW54; Escherichia coli
BW55, Acinetobacter hemolyticus BW62; Stenotrophomonas
maltophilia D457R; and Gram positive bacterial pathogens:
Staphylococcus epidermis 887E, bacillus cereus ATCC
11778, Staphylococcus aureus ATCC 29213 and Sarcina lutea.
Ciproﬂoxacin (Cipro) and chloramphenicol (Chlor) were used
as positive reference standards. The tested compounds and
the drugs were used at a concentration 10 lmol mL1
(DMSO). Antimicrobial tests were carried out by the agar well
diffusion method (Perez et al., 1990) using 100 mL of a suspen-
sion of the proper LB nutrient broth (the medium that is used
to grow bacteria) containing 1 · 108 CFU mL1 bacteria. The
antimicrobial activity was evaluated by measuring the zone of
inhibition against the tested organisms and compared with
that of the standards. Antimicrobial activities were expressed
as the inhibition diameter zones in millimeters (mm) and pre-
sented in Table 1. Each experiment was carried out in triplicate
and the average zone of inhibition was calculated.
2.3.2. Minimal inhibitory- (MIC, lmol L1) and minimal
bactericidal concentration (MBC, lmol L1) evaluation
The bacteriostatic activity of the most active compounds 5a–5d,
5g, and 5h, Cipro and Chlor was determined by the broth
microdilution method on 96-well polystyrene ﬂatbottommicro-
titer plates (Sarstedt, Germany), according to Clinical
Laboratory Standards Institute (CLSI) guidelines speciﬁca-
tions (Scott, 1989). The antimicrobial activity was assessed
for each compound in the range of concentration from 450 to
10 lmol L1 (450, 200, 100, 50, 25, 10 lmol L1) in cation-
adjusted Mueller Hinton (MH) medium (Fluka). Overnight
cultures incubated at 30 C or 37 C as appropriate in MH,
were standardized to 0.5 McFarland units at 625 nm. Each
compound-containing well and the positive control wells werePlease cite this article in press as: Abdou, W.M., Bekheit, M.S. One-pot three-comp
plastic properties. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.inoculated with 2 · 108 CFU. Each plate included the positive
control (bacteria without the antimicrobial) and the negative
controls (medium only). MIC was recorded as the lowest con-
centration of compound that did not result in an observed opti-
cal density (OD) at a wavelength (k) of 595 nm higher than its
respective control with compound only after 24 h of incubation
at 37 C. Each assay was performed in triplicate. A strain is
considered multi-resistant when it is non-susceptible to at least
3 different classes of antimicrobial agents. The lowest concen-
tration showing no growth was taken as the minimum inhibi-
tory concentration (MIC lmol L1).
After 24 h of incubation, a spotting essay was performed in
order to evaluate minimum bacterial concentration (MBC).
Plates were prepared using LB nutrient broth solid medium,
dried on a laminar ﬂux chamber and inoculated with 5 mL
of the content of each microplate pit. Plates were incubated
at 37 C overnight for CFU counting. MBC was recorded as
the lowest concentration used that did not result in an eye-
observable culture in solid medium after 24 h of incubation.
Each assay was performed in triplicate. Data of MIC
(lmol L1)/MBC (lmol L1) are presented in Table 2.
2.3.3. Antitumor activity screening
Antitumor potency of selected phosphonates 5a–5d, 5f, 5g, 5j,
6a and 7a was tested at a dose of 10 lmol L1 (DMSO) utiliz-
ing 8 different human tumor cell lines. These lines represent
breast (MCF7, MDA-MB-435, BT-549), ovarian (IGROVI,
SK-OV-3), prostate (PX-3, PU-145), and liver (HEPG2). 5-
Fluorouracil was used as a positive reference according to
the reported methods (Kitamura et al., 2004; Boyd and
Paull, 1995) (Table 3). Using absorbance measurements at a
wavelength (k) 515 nm for each compound for the control
growth and for the test growth, the percentage growth inhibi-
tion is calculated at each of the tested compound concentra-
tion level. The susceptibility testing assays were undertaken
three times. Growth inhibition of 50% (GI50 lmol L
1) was
calculated. Further studies on experimental tumors in vivo
for evaluating the possible antineoplastic potential of the most
promising compounds are in progress.
3. Results and discussion
3.1. Chemistry
We have focused, in this work on the synthesis of
dialkoxyphosphoryl peptides. The demand for modiﬁed pep-
tides with improved stability proﬁles and pharmacokinetic
properties is driving extensive research efforts in this ﬁeld.
Many structural modiﬁcations of peptides guided by rational
design and molecular modeling have been established to
develop novel synthetic approaches (Goodman, 2003).
Our targets, dialkoxyphosphoryl peptides 5a–5j were
obtained using the three component reaction of 3-
(benzofuran-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde (1),
dialkyl phosphites 2a, 2b and isothiocyanates 3a–3d (or iso-
cyanates 3e), successively in tetrahydrofuran (THF) containing
potassium carbonate (K2CO3). Obviously, the phosphonates 5
were observed through the initial formation of the a-hydroxyhy
drocarbylphosphonates 4 via the nucleophilic addition of the
phosphite reagent to the aldehyde, followed by the hydrophos-
phonylation of the imine function of 3 (Scheme 1) (Kaboudinonent synthesis of peptidomimics for investigation of antibacterial and antineo-
arabjc.2015.04.014
Table 1 Zone of growth inhibition (mm)a of the phosphor esters 5a–5j, 6a, 6b, 7a and 7b, Cipro, and Chlor against some bacteria.
Cmpd. Strain (Gram-negative) Strain (Gram-positive)
K.
pneumoniae
2011E
P.
aeruginosa
6065Y
E. coli
BW54
E. coli
BW55
A.
hemolyticus
BW62
S.
maltophilia
D457R
S.
epidermis
887E
B. cereus
ATCC 11778
S. aureus
ATCC 29213
Sarcina
lutea
Cipro 12 9 11 11 10 9 10 14 12 12
Chlor 10 8 11 7 9 9 12 11 10 10
5a 13 10 12 11 12 10 13 14 14 9
5b 14 10 12 9 11 8 11 12 12 10
5c 10 9 8 7 8 11 6 6 8 7
5d 9 8 10 8 7 6 7 9 7 11
5e 6 5 8 6 8 5 4 6 5 4
5f 6 4 5 6 7 6 4 4 5 7
5g 11 8 10 8 9 6 11 10 10 9
5h 6 7 4 5 5 6 4 6 6 8
5i 8 6 6 7 8 4 5 6 5 7
5j 8 6 6 7 5 4 6 7 5 6
6a 6 8 6 7 5 7 4 6 7 7
6b 7 5 8 4 6 5 7 5 64b 6
7a 64 64 64 64 64 64 64 64 64 64
7b 64 64 64 64 64 64 64 64 64 64
a Concentration of each used compound is 10 lmol L1 (DMSO).
b Compounds, which have <4 mm growth inhibition, were considered inactive.
Table 2 MIC (lmol L1)/MBC (lmol L1) of the phosphonates 5a–d, 5g, 5h, Cipro and Chlor against some bacteria.
Strains Cipro Chlor 5a 5b 5c 5d 5g 5h
K. pneumoniae 2011E 90.6/90.6 55.7/99 61.5/76.4 56.1/176.3 65.9/65.9 97.5/124.7 82.5/375.2 137.2/196.1
P. aeruginosa 6065Y 102.7/187.3 99/99 59.4/138 66.1/100.2 65.9/65.9 124.7/194.9 82.5/375.2 114.1/114.1
E. coli BW54 193.3/193.3 49.5/198.1 42.5/67.9 60.1/200.4 61.8/131.9 68.2/116.9 56.3/120 114.1/213.9
E. coli BW55 362.5/368.5 396.2/396.2 186.8/233.5 128.2/128.2 61.8/131.9 124.7/249.5 60/60 114.1/228.1
A. hemolyticus BW62 362.5/694.9 37.1/46.4 259/329 56.1/56.1 61.8/65.9 48.7/62.4 131.3/375.2 245.9/445.6
S. maltophilia D457R 96.7/135.9 123.8/123.8 63.7/106.1 48.1/66.1 90.7/263.9 62.4/389.9 131.3/375.2 114.1/114.1
S. epidermis 887E 377.6/543.8 191.9/433.4 159.2/271.8 156.3/354.7 185.6/131.9 257.3/194.9 326.4/422.1 276.3/415.3
B. cereus ATCC 11778 66.5/193.3 111.4/173.4 50.9/127.4 160.3/200.4 65.9/131.9 85.7/194.9 75/187.6 228.2/356.5
S. aureus ATCC 29213 181.2/181.2 198.1/619.2 93.4/163.5 92.2/200.4 90.7/113.4 128.6/ 194.9 112.6/120 228.2/356.5
Sarcina lutea 96.7/377.6 198.1/619.2 53.1/212.3 80.1/220.4 82.4/181.4 140.3/ 389.9 103.2/375.2 115.8/392.1
6 W.M. Abdou, M.S. Bekheitand Nazari, 2001; Li et al., 2008). In the IR (mmax cm
1, KBr)
spectra of 5a–5j, NH bond was observed at about 3421–3332
while the thiocarbamyl (C‚S) bond was displayed within
1138–1124 (5a–5h) whereas the carbonyl bonds of 5i and 5j
appeared at 1703 and 1742. In the NMR spectra (d ppm) of
5b ‘‘as a representative example’’, the exocyclic methine moiety
‘‘chiral’’ was found at dH = 5.63 (d,
2JPAH = 17.8 Hz) and at dc
70.1 (d, 1JPAC = 120.6 Hz). N-Methyl protons appeared as a
singlet at 3.36 (3H) and at dc 31.6.
13CNMR spectrum of 5b also
showed the signals at 180.4 (d, 3JPAC = 8.4 Hz, C‚S), 136.1
(3JPAC = 8.8 Hz, C(3)-pyrazole) pm. The
31P NMR spectrum
of 5b showed a positive signal at dP = 23.9 ppm (vsH3PO4) that
indicates the phosphonate structure. Finally, compound 5b was
correctly identiﬁed as C24H26N3O5PS, {m/z (%): 499 (23) [M
+],
498 (35) [M+  1], and the base peak at 288 (100)
[M+  (C(S)NHMe + P(O)(OET)2)]}.
On the other hand, when the unsaturated isothiocyanate 3f
was applied in the above reaction with pyrazole-4-carbaldehyde
1 and dialkyl phosphites 2a, 2b, the phosphonates 6a, 6b werePlease cite this article in press as: Abdou, W.M., Bekheit, M.S. One-pot three-comp
plastic properties. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.produced in 70 and 74 yields. Compounds 6a, 6b were derived
from the rearrangement of 5k and 5l (Scheme 2). Structure 6a
was clearly veriﬁed by its NMR spectra. 1H NMR (d ppm)
did not show any of NH signal and revealed no D2O exchanges.
However, the two methoxyl (P(OMe)2) protons displayed as
two doublets (3JPAH = 11.8 Hz, 2 · 3H) at 3.66, 3.68 whereas
the ethyl (N‚CHAC2H5) protons resonated at 2.33 (t,
JHAH = 6.7 Hz, 3H, MeCH2) and 3.44 (m, 2H, H2C-Me).
The imine proton (N‚CH) appeared as a triplet at 6.46 ppm
(t, JHAH = 6.6 Hz, 1H, N‚CH-exocycl).
13C NMR spectrum
of 6a showed among others C‚S (d, 3JPAC = 7.5 Hz) at
186.2, and N = CH at 164.8 ppm.
Structure 6a was clearly veriﬁed by its NMR spectra. 1H
NMR (d ppm) did not show any of NH signal and revealed
no D2O exchanges. However, the two methoxyl (P(OMe)2)
protons displayed as two doublets (3JPAH = 11.8 Hz, 2 · 3H)
at 3.66, 3.68 whereas the ethyl (N‚CHAC2H5) protons res-
onated at 2.33 (t, JHAH = 6.7 Hz, 3H, MeCH2) and 3.44 (m,
2H, H2C-Me). The imine proton (N‚CH) appeared as aonent synthesis of peptidomimics for investigation of antibacterial and antineo-
arabjc.2015.04.014
Table 3 Concentrations resulting in growth inhibition of 50% (IC50 lmol L
1)a,b of in vitro human tumor cell lines of 5a, 5b, 5c, 5d,
5f, 5g, 5j, 6a, 7a.
Panel/Cell line Control Compounds
Vehicle Fc 5a 5b 5c 5d 5f 5g 5j 6a 7a
Breast cancer
MCF7 – 17.7 16.6 17.2 21.8 28 31.4 34.3 31.5 36.6 58.2
MDA-MB-435 – 27.7 23.3 22.3 13.6 24.2 24.7 34.7 28.4 36.4 65.4
BT-549 – 23.6 22.7 29.4 35.7 36.6 20.4 20.2 29.3 33.4 67.3
Ovarian cancer
IGROVI – 38.8 24.6 29.2 29.9 24.6 24.2 40.3 51.9 47 60.3
SK-OV-3 – 27.4 26.9 36.9 34 40 23.6 58.2 55.8 55.5 69.4
Prostate cancer
PX-3 – 22.9 22.7 17.4 23 13.4 27.9 34.1 26 53.7 37.9
PU-145 – 27.5 20.1 28.8 19.6 15.6 24.6 29.3 28.4 36.6 65.2
Liver cancer
HEPG2 – 25.5 18.2 26.8 29.9 23.8 36.3 22.3 42.7 67.8 62.2
a Cell line growth inhibition with >50% at a concentration of 10 lmol L1 was considered to be a noticeable activity.
b Data are presented as the means of three independent experiments.
c F: 5-Fluorouracil.
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Scheme 1 Synthesis of the phosphonates 5a–5j.
Peptidomimics vs microbial and cancer diseases 7triplet at 6.46 ppm (t, JHAH = 6.6 Hz, 1H, N‚CH-exocycl).
13C NMR spectrum of 6a showed among others C‚S (d,
3JPAC = 7.5 Hz) at 186.2, and N‚CH at 164.8 ppm.
Next, we applied the same protocol to the reaction of the
aldehyde 1, dialkyl phosphites 2a, 2b and acetic anhydride
(instead of the cyanate)/K2CO3, using the same ratio
1:1:1:1.5. The reaction proceeded smoothly in 1–3 h at room
temperature to give a-acetoxyphosphonates 7a and 7b in 82%
and 86% yields (Scheme 3). Structure 7was apparent from their
mass spectra, which displayed, in each case, the molecular ionPlease cite this article in press as: Abdou, W.M., Bekheit, M.S. One-pot three-comp
plastic properties. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.peak at appropriate m/z values. Its 1H NMR (d ppm) spectrum
exhibited two doublets (3JPAH = 11.0 Hz, 2 · 3H) at 3.73, 3.78
that readily recognized as arising from the two diastereotopic
methoxyl groups attached to phosphorus [(MeO)2P].
The singlet at 2.12 belongs to the methyl ester protons. The
a-methine proton is coupled to the phosphorus atom and it
showed up as a doublet at 6.64 (2JPAH = 14.6 Hz). The
proton-decoupled 13C NMR spectrum of 7a showed distinct
resonances in agreement with the proposed structure. 31P
NMR shift of 7a was recorded at dp 26.7 ppm.onent synthesis of peptidomimics for investigation of antibacterial and antineo-
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+ +
THF/K2CO3
r.t.
N
N
Ph
O
P(OR)2
O
Z
N
S
1 2
3f
6a,6b
Et
a,R=Me; b,R=Et
N
N
Ph
O
P(OR)2
O
Z H
N
S
5k,5l
S
C
N
Scheme 2 Synthesis of the phosphonates 6a and 6b.
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3.2.1. Antimicrobial evaluation
A preliminary screening of new compounds 5a–5j, 6a, 6b, 7a
and 7b was evaluated in vitro against a panel of standard
and clinically isolated strains of Gram-negative and Gram-
positive bacteria. The antibiotic activity was executed using
the disk diffusion method (Perez et al., 1990) and the results
are recorded in Table 1. All tested phosphonates exhibited
moderate to good antimicrobial activity. The measurement
of the zone of growth inhibition for a concentration
10 lmol mL1 (DMSO) of each compound showed that phos-
phorylthiocarbamates 5a–5d, followed by phosphorylcarba-
mates 5i and 5j are the most active compounds that inhibited
the growth of Gram-negative and/or Gram-positive. The order
of activity into the series of the thiocarbamates is
5a> 5b> 5c> 5d> 5g> 5h> 5e> 5f> 6a> 6b. Four
top active compounds 5a–5d were selected for further screen-
ing of minimum concentrations of each compound required
to inhibit growth (MIC lmol L1). They all have in common
the thiocarbamate moiety, which suggests that the presence
of this motif may be enhancing the activity. Even compounds
5g and 5h, which were less active, were also selected for
comparison.
The minimum concentrations of each compound required to
inhibit growth (MIC lmol L1) and the minimum bactericidal
concentrations of each compound i.e., the concentration
required to kill each pathogen (MBC lmol L1) were then deter-
mined for the phosphonates 5a–5d and 5g, 5h as well as the two
reference drugs ciproﬂoxacin (Cipro) and chloramphenicol
(Chlor). The activity was assessed for each drug in the range of
concentration from 450 to 10 lmol L1 (450, 200, 100, 50, 25,
10 lmol L1) in cation-adjustedMueller Hinton (MH) medium
(Fluka) (Scott, 1989) and the results are displayed in Table 2.Z
N
N
CHO
+ HP(OR)2
O
+
Ph
1
2a,2b
Ac2O
Scheme 3 Synthesis of the
Please cite this article in press as: Abdou, W.M., Bekheit, M.S. One-pot three-comp
plastic properties. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.Datadisplayed inTables 1 and2 showed that themost twoactive
phosphonates are 5a and 5b with MIC 42.5–259 lmol L1 and
48.1–160.3 lmol L1 values whereas their MBC values are
67.967.–329 and 56.1–354.7 lmol L1 against all pathogens
tested. For comparison, MIC/MBC for ciproﬂoxacin were
recorded at 66.5–377.6 (MIC, lmol L1) and at 90.6–694.9 for
MBC lmol L1 values. On the other hand,MIC/MBC for chlo-
ramphenicol were recorded at 37.1–396.2(MIC, lmol L1) and
at 46.4–619.2 for MBC lmol L1.
3.2.2. Antitumor activity
The IC50 values (concentration required to inhibit tumor cell
proliferation by 50%) for nine of the synthesized compounds
(5a–5d, 5f, 5g, 5j, 6a, and 7a) against eight human cancer cell
lines including MCF7, MDA-MB-435, BT-549 (human breast
carcinoma cell lines), IGROVI, SK-OV-3 (human ovarian car-
cinoma cell lines), PX-3, PU-145 (human prostate carcinoma
cell lines), and HEPG2 (human liver carcinoma cell line) were
determined at a dose of 10 lmol L1 (DMSO) in assays
according to the reported methods (Kitamura et al., 2004;
Boyd and Paull, 1995). The IC50 values are listed in Table 3
and the well known anticancer drug 5-ﬂuorouracil was used
as a positive control. From the screening results in Table 3,
it was observed that compounds 5a–d exhibited good to signif-
icant anticancer activity against the eight tested human cancer
cell lines. Two of the most active compounds are 5a and 5b
with IC50 values against the eight tested human cancer cell
lines ranging from 16.6 to 26.9 and 17.2 to 36.9 lmol L1,
respectively (for 5-ﬂuorouracil IC50: 17.7–38.8). Compound
5a was more cytotoxic than 5-ﬂuorouracil against all tested
eight human cancer cell lines while 5b was more active than
5-ﬂuorouracil only in the case of MDA-MB-, IGROVI and
PX-3. On the other hand, a-acetoxyphosphonate 7a showed
a dramatic drop of potency. Replacing the alky substituentTHF/K 2CO3
r.t.
N
N
Ph
O
P(OR)2
O
Z
Me
7a,7b
a,Me; b,Et
O
phosphonates 7a and 7b.
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slight loss of the IC50 values (5f, 5g). Nevertheless, the sub-
stituent at the isothiocyanates has a profound inﬂuence on
anticancer activity, such as 5a (16.6 lmol) as compared to 6a
(36.6 lmol) against MCF7. However, phosphoryl carbamates
5j showed weak or no cytotoxicity against all tested cell lines.
It is worth mentioning that it is for the ﬁrst time to obtain
phosphonates of remarkable potency against human liver car-
cinoma cell line.
In parallel, similar to antitumor data, the antibiotic results
showed that phosphorylthiocarbamates 5a and 5b possess the
highest activity than their phosphorylcarbamates-counterparts
6a, 6b or a-acetoxyphosphonate 7a. On the other hand, while
5g showed good potency against all tested pathogens, antitu-
mor efﬁcacy was only noticeable for this compound. At this
point, a straight correlation between tumor activity and antibi-
otic efﬁcacy of the tested phosphonates was not found. This
result is not surprising, since the targets of these two activities
should be different. Furthermore, the observed antibacterial
activity, albeit weak, can be the result of non-speciﬁc cytotoxic
effects (e.g., 6a, 6b and 7a, 7b), as bacteria can be killed in
many ways.
Considering the structure–activity relationship (SAR), as
shown in Tables 1–3, the highest protection was observed for
5a, followed by 5b and 5c. It seems that the phosphonate
group is essential for the biological activity. As far as cyclic
substituted pyrazol-based phosphonate is concerned, it is obvi-
ous that substituents of the phosphonate moiety determine
potency. Thus, the presence of C(S)N group is favorable in this
series of compounds. The introduction of hexyl or phenyl sub-
stituent to the exo-cyclic amino group led to compounds 5g, 5h
with decrease activity. Nevertheless, the introduction of both
C(O)N and phenyl moieties was totally unfavorable and dra-
matically decreased the antiinﬂammatory and the antitumor
potencies of compounds 5i and 5j.
4. Conclusion
In summary, we have synthesized three types of new phospho-
nate derivatives: a-phosphorylthiocarbamates (5a–h, 6a, 6b), a-
phosphorylcarbamates (5i, 5j), and a-acetoxyphosphonates
(7a, 7b). The described method is efﬁcient and high yielding
for the one-pot approach from aldehyde, dialkyl phosphites
and cyanates or acetic anhydride using potassium carbonate.
Representative examples of the new class of phosphonates
were screened for anticancer activity against eight human can-
cer cell lines. Compounds 5a and 5b exhibited excellent broad
spectrum of anticancer activity in vitro, especially compound
5a, which was more potent than 5-ﬂuorouracil against all
tested human cancer cell lines.
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